Default Question Block

KESETT Start up Site Survey

Congratulations! The KESETT grant is expected to be awarded in January 2025. This purpose of this survey is to confirm your interest in being a site and update your information if you previously expressed interest and provided a letter of support. We are also using this survey to collect information from sites that did not previously express interest, or that provided a letter too late to be included the first time around, but that are now interested in being a replacement or add on site.

This survey will ask for the names and emails of an emergency medicine investigator and a neurology investigator at your site, a study coordinator contact (if you have one), a contracts or administrative contact, and an IT contact that will be involved with implementation of rapid EEG for research. We intend to start up the trial as quickly as possible, and plan to incentivize rapid site start up. Please complete this survey by January 10, 2025.

Here is link to a list of sites that provided LOS and were included in the grant submission. However, your site may not be on this list if you told us of your interest and provided a LOS too late to be included in the submission.

Ketamine in Established Status Epilepticus Treatment Trial (KESETT) Summary

KESETT is a proposed prospective randomized controlled adaptive dose-selection clinical trial to determine the efficacy of adding ketamine to levetiracetam in patients with benzodiazepine refractory status epilepticus in the emergency department. Ketamine has potent anti-seizure properties in preclinical models and in observational clinical studies, is familiar to emergency physicians and widely used for other indication, and of great interest to the status epilepticus community. The trial will enroll a patient population of adults and children similar to those enrolled in the previous ESETT trial, and integration of the trial into emergency care will be implemented in a similar way. KESETT however adds an early EEG outcome. KESETT, like ESETT, is an exception from informed consent (EFIC) trial, and will involve sites conducting community consultation and public disclosure activities, but this time with a single central IRB per NIH policy. We are looking primarily to engage former ESETT sites, SIREN sites, and PECARN sites, but will consider other well qualified sites as well. We initially anticipate 60 trial sites, but will consider adding sites as resources permit. Sites listed in the grant application will have priority for participation in the trial.
A clinical trial synopsis with more detail is available by clicking here.

Please respond to this survey by January 10, 2025.

Please select your institution from the following list of sites previously signed in to participate.

If your site is interested in participating but is not on this list, then select 'my hospital is not on this list - add spoke' at the bottom of the list)

If your hospital is not listed above, what is the name of your hospital?

Is your site still interested in participating in KESETT?

- ○ Yes, We are still interested!
- ○ No. Unfortunately we are no longer interested in participating.
- ○ We didn't provide a letter of support the first time around, but are interested now.

Most KESETT sites are affiliated with a PECARN Research Node **and/or** a SIREN Award Hub Community.

Is your site already associated with a **SIREN Award Hub Community**, and if so, which one?

Given the nature of this trial, a lead Neurologist (Epileptologist or Neurointensivist) and a lead Emergency Medicine investigator are expected at all sites interested in participating. Please confirm the name and email for both.

Neurology lead investigator name?

Neurology lead investigator email?

Emergency Medicine lead investigator name?

Emergency Medicine lead investigator email?

If there is a site PI other than the investigators listed above, who is that? Please provide the name, specialty, and email addresss? (if not, leave blank)

If you have identified a primary study coordinator, we would like to include them in future emails.

Primary study coordinator contact name?

Primary study coordinator contact email?

If you have an individual that assists in research administration and contracting, we would like to include them in future emails.

Research administrator or contracting contact name?

Research administrator or contracting contact email?

KESETT will enroll both adults and children. Emergency departments that care for adults can only enroll children if they also have a dedicated pediatric care area and resources. What ages does your site intend to enroll?

- ○ Only adults
- ○ Only children
- ○ Both adults and children (in a dedicated pediatric emergency care area)

Did your site enroll patients in ESETT?

- ○ Yes
- ○ No

Does your site and study team have experience enrolling in other trials with Exception From Informed Consent (EFIC)

- ○ No, EFIC is new to us
- ○ Yes, we have enrolled in other EFIC trials

Does your site already use, or have access to, rapid EEG in clinical practice (Ceribell device or similar device)? This will be used in the trial, but we don't expect or need your site to be using this now or have any prior experience.

- ○ No, we do not use a rapid EEG in clinical practice at our institution
- ○ Yes, we use Ceribell at our institution
- ○ Yes, we use Zeto at our institution
- ○ Yes, we use another rapid EEG device

You indicated that you use a rapid EEG device other than Ceribell or Zeto at your institution. What rapid EEG device does your institution use?

You indicated that rapid EEG is used at your institution. How often is it used in the Emergency Department?

- ○ Routinely used in the ED
- ○ Rarely used in the ED
- ○ Used in other units but not in the ED

In future communications with you about the use of rapid EEG for research purposes, including networking and connectivity, we would like to include an IT contact at your institution.

Information technology contact (regarding rapid EEG implementation) name?

Information technology contact regarding rapid EEG implementation email?

Person completing this survey

Email address of person completing survey